China Immunotech (beijing) Biotechnology Co., Ltd.

This early-stage study tests a new cell therapy called YTS109 in 18 adults with hard-to-treat autoimmune diseases like lupus and Sjogren's syndrome. Participants receive a single infusion of these specially designed cells. The main goal is to see if the treatment is safe, and res…

This early-stage study tests a new cell treatment called YTS109 in about 18 adults with autoimmune diseases like lupus or scleroderma that have not responded to standard therapies. Participants receive a single infusion of these modified immune cells. The main goal is to check sa…

This early-stage study is testing a new cell therapy called YTS109 in 18 adults with severe autoimmune diseases like lupus and Sjogren's syndrome that have not responded to standard treatments. Participants receive a single infusion of these specially designed immune cells. The m…